Details of the Drug

General Information of Drug (ID: DMB4OLE)

Drug Name
Propofol
Synonyms
Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Leukemia N.A. Approved [2]
Traumatic brain injury NA07.Z Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 178.27
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 36 mL/min/kg [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.2 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.02315 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.016% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.7 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.164 mg/mL [4]
Chemical Identifiers
Formula
C12H18O
IUPAC Name
2,6-di(propan-2-yl)phenol
Canonical SMILES
CC(C)C1=C(C(=CC=C1)C(C)C)O
InChI
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
InChIKey
OLBCVFGFOZPWHH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4943
ChEBI ID
CHEBI:44915
CAS Number
2078-54-8
DrugBank ID
DB00818
TTD ID
D0A3HB
VARIDT ID
DR00424
INTEDE ID
DR1365
ACDINA ID
D01367
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fatty acid amide hydrolase (FAAH) TTDP1UC NOUNIPROTAC Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [15]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [12]
Oleamide hydrolase 1 (FAAH) DEUM1EX FAAH1_HUMAN Substrate [16]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2) OTTG0NFD S5A2_HUMAN Gene/Protein Processing [17]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [18]
Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (MGAT5) OTU4DD4G MGT5A_HUMAN Gene/Protein Processing [18]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [19]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [19]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Gene/Protein Processing [20]
Carbonic anhydrase 1 (CA1) OTNFBVVQ CAH1_HUMAN Gene/Protein Processing [21]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Gene/Protein Processing [21]
Carbonic anhydrase 5A, mitochondrial (CA5A) OTP9M7VW CAH5A_HUMAN Gene/Protein Processing [17]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anaesthesia
ICD Disease Classification 9A78.6
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fatty acid amide hydrolase (FAAH) DTT NO-GeName 2.65E-01 0.02 0.1
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 7.90E-01 3.72E-02 2.95E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 9.06E-01 -5.05E-02 -1.20E-01
Oleamide hydrolase 1 (FAAH) DME FAAH 2.65E-01 2.41E-02 1.04E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 3.17E-01 -6.95E-02 -2.88E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 5.79E-01 -1.30E-02 -9.78E-02
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.21E-02 9.40E-02 6.62E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.68E-01 3.64E-02 2.72E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.83E-01 2.32E-03 1.53E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Propofol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Desflurane DM2TO9R Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Desflurane. Corneal disease [9A76-9A78] [22]
Halothane DM80OZ5 Moderate Additive CNS depression effects by the combination of Propofol and Halothane. Corneal disease [9A76-9A78] [22]
Sevoflurane DMC9O43 Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Sevoflurane. Corneal disease [9A76-9A78] [22]
Methoxyflurane DML0RAE Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Methoxyflurane. Corneal disease [9A76-9A78] [22]
Ketamine DMT5HA4 Moderate Additive CNS depression effects by the combination of Propofol and Ketamine. Corneal disease [9A76-9A78] [22]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Propofol and Remifentanil. Corneal disease [9A76-9A78] [22]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Propofol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased risk of prolong QT interval by the combination of Propofol and Ivosidenib. Acute myeloid leukaemia [2A60] [23]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Propofol and Midostaurin. Acute myeloid leukaemia [2A60] [23]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Propofol and Idarubicin. Acute myeloid leukaemia [2A60] [23]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Propofol and Arn-509. Acute myeloid leukaemia [2A60] [23]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Propofol and Gilteritinib. Acute myeloid leukaemia [2A60] [23]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Propofol and Oliceridine. Acute pain [MG31] [24]
Rivastigmine DMG629M Moderate Increased risk of prolong QT interval by the combination of Propofol and Rivastigmine. Alzheimer disease [8A20] [23]
Donepezil DMIYG7Z Moderate Increased risk of prolong QT interval by the combination of Propofol and Donepezil. Alzheimer disease [8A20] [23]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Propofol and Metronidazole. Amoebiasis [1A36] [25]
Bepridil DM0RKS4 Moderate Increased risk of prolong QT interval by the combination of Propofol and Bepridil. Angina pectoris [BA40] [23]
Dronedarone DMA8FS5 Moderate Increased risk of prolong QT interval by the combination of Propofol and Dronedarone. Angina pectoris [BA40] [23]
Bedaquiline DM3906J Moderate Increased risk of prolong QT interval by the combination of Propofol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [23]
Methylphenobarbital DMDSWAG Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [26]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Propofol and Chlormezanone. Anxiety disorder [6B00-6B0Z] [22]
Oxazepam DMXNZM4 Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Oxazepam. Anxiety disorder [6B00-6B0Z] [22]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Propofol and Cilostazol. Arterial occlusive disease [BD40] [23]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Propofol and Posaconazole. Aspergillosis [1F20] [23]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Levalbuterol. Asthma [CA23] [27]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Terbutaline. Asthma [CA23] [28]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Propofol and Pirbuterol. Asthma [CA23] [28]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Propofol and Salbutamol. Asthma [CA23] [27]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Formoterol. Asthma [CA23] [28]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Propofol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [29]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Propofol and Ofloxacin. Bacterial infection [1A00-1C4Z] [23]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Propofol and Clarithromycin. Bacterial infection [1A00-1C4Z] [23]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Propofol and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [30]
Sparfloxacin DMB4HCT Moderate Increased risk of prolong QT interval by the combination of Propofol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [23]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Propofol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [23]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Propofol and Norfloxacin. Bacterial infection [1A00-1C4Z] [23]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Propofol and Levofloxacin. Bacterial infection [1A00-1C4Z] [23]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Propofol and Lomefloxacin. Bacterial infection [1A00-1C4Z] [23]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Propofol and Telithromycin. Bacterial infection [1A00-1C4Z] [23]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Propofol and Loperamide. Bowel habit change [ME05] [31]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Propofol and Eribulin. Breast cancer [2C60-2C6Y] [23]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Propofol and Lapatinib. Breast cancer [2C60-2C6Y] [23]
Alpelisib DMEXMYK Moderate Increased metabolism of Propofol caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Propofol and Bosutinib. Breast cancer [2C60-2C6Y] [23]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Propofol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [23]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [28]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [27]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Propofol and Salmeterol. Chronic obstructive pulmonary disease [CA22] [28]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [28]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [28]
Dihydrocodeine DMB0FWL Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Dihydrocodeine. Chronic pain [MG30] [26]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Isoproterenol. Conduction disorder [BC63] [27]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Propofol and Probucol. Coronary atherosclerosis [BA80] [23]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Propofol and Clofazimine. Crohn disease [DD70] [23]
Mifepristone DMGZQEF Moderate Decreased metabolism of Propofol caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [32]
Pasireotide DMHM7JS Moderate Increased risk of prolong QT interval by the combination of Propofol and Pasireotide. Cushing syndrome [5A70] [23]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Propofol and Osilodrostat. Cushing syndrome [5A70] [23]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Propofol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [33]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Propofol and Ethanol. Cystitis [GC00] [34]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Propofol and Sertraline. Depression [6A70-6A7Z] [23]
Escitalopram DMFK9HG Moderate Increased risk of prolong QT interval by the combination of Propofol and Escitalopram. Depression [6A70-6A7Z] [23]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Propofol and Doxepin. Depression [6A70-6A7Z] [35]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Propofol and Esketamine. Depression [6A70-6A7Z] [25]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Propofol and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [26]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Propofol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [23]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Propofol and Deutetrabenazine. Dystonic disorder [8A02] [23]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Propofol and Ingrezza. Dystonic disorder [8A02] [23]
Diazepam DM08E9O Moderate Additive CNS depression effects by the combination of Propofol and Diazepam. Epilepsy/seizure [8A61-8A6Z] [22]
Cenobamate DM8KLU9 Moderate Increased metabolism of Propofol caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Propofol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [22]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Propofol and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [22]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Propofol and Solifenacin. Functional bladder disorder [GC50] [23]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Propofol and Ketoconazole. Fungal infection [1F29-1F2F] [23]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Propofol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [23]
Saquinavir DMG814N Moderate Increased risk of prolong QT interval by the combination of Propofol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [23]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Propofol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Propofol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [23]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Propofol and Suvorexant. Insomnia [7A00-7A0Z] [22]
Amobarbital DM0GQ8N Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Amobarbital. Insomnia [7A00-7A0Z] [22]
Ramelteon DM7IW9J Moderate Additive CNS depression effects by the combination of Propofol and Ramelteon. Insomnia [7A00-7A0Z] [22]
Triazolam DMETYK5 Moderate Additive CNS depression effects by the combination of Propofol and Triazolam. Insomnia [7A00-7A0Z] [22]
Zaleplon DMGFWSM Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Zaleplon. Insomnia [7A00-7A0Z] [22]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Propofol and Tasimelteon. Insomnia [7A00-7A0Z] [22]
Paraldehyde DMOC1BX Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Paraldehyde. Insomnia [7A00-7A0Z] [22]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Propofol and Quazepam. Insomnia [7A00-7A0Z] [22]
Estazolam DMZGXUM Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Estazolam. Insomnia [7A00-7A0Z] [22]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Polyethylene glycol. Irritable bowel syndrome [DD91] [29]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Phenolphthalein. Irritable bowel syndrome [DD91] [30]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Propofol and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [24]
Crizotinib DM4F29C Moderate Decreased metabolism of Propofol caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
Ceritinib DMB920Z Moderate Increased risk of prolong QT interval by the combination of Propofol and Ceritinib. Lung cancer [2C25] [23]
PF-06463922 DMKM7EW Moderate Increased metabolism of Propofol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [29]
Osimertinib DMRJLAT Moderate Increased risk of prolong QT interval by the combination of Propofol and Osimertinib. Lung cancer [2C25] [23]
Lumefantrine DM29GAD Moderate Increased risk of prolong QT interval by the combination of Propofol and Lumefantrine. Malaria [1F40-1F45] [35]
Halofantrine DMOMK1V Moderate Increased risk of prolong QT interval by the combination of Propofol and Halofantrine. Malaria [1F40-1F45] [23]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Propofol and Hydroxychloroquine. Malaria [1F40-1F45] [23]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Propofol and Primaquine. Malaria [1F40-1F45] [23]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Propofol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [23]
Arsenic trioxide DM61TA4 Moderate Increased risk of prolong QT interval by the combination of Propofol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [23]
Vemurafenib DM62UG5 Moderate Increased risk of prolong QT interval by the combination of Propofol and Vemurafenib. Melanoma [2C30] [23]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Propofol and LGX818. Melanoma [2C30] [23]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Propofol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [29]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Propofol and Flibanserin. Mood disorder [6A60-6E23] [22]
Panobinostat DM58WKG Moderate Increased risk of prolong QT interval by the combination of Propofol and Panobinostat. Multiple myeloma [2A83] [23]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Propofol and Thalidomide. Multiple myeloma [2A83] [37]
Siponimod DM2R86O Moderate Increased risk of prolong QT interval by the combination of Propofol and Siponimod. Multiple sclerosis [8A40] [23]
Fingolimod DM5JVAN Moderate Increased risk of prolong QT interval by the combination of Propofol and Fingolimod. Multiple sclerosis [8A40] [23]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Propofol and Ozanimod. Multiple sclerosis [8A40] [38]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Propofol and Romidepsin. Mycosis fungoides [2B01] [23]
Nilotinib DM7HXWT Moderate Increased risk of prolong QT interval by the combination of Propofol and Nilotinib. Myeloproliferative neoplasm [2A20] [23]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Propofol and Dasatinib. Myeloproliferative neoplasm [2A20] [23]
Prasugrel DM7MT6E Minor Decreased metabolism of Propofol caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [29]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Propofol and Promethazine. Nausea/vomiting [MD90] [23]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Propofol and Granisetron. Nausea/vomiting [MD90] [23]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Propofol and Ondansetron. Nausea/vomiting [MD90] [23]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Propofol and Entrectinib. Non-small cell lung cancer [2C25] [25]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Propofol and Levomethadyl Acetate. Opioid use disorder [6C43] [26]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Propofol and Lofexidine. Opioid use disorder [6C43] [23]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Propofol and Apraclonidine. Optic nerve disorder [9C40] [39]
Olaparib DM8QB1D Moderate Increased metabolism of Propofol caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [25]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Propofol and Rucaparib. Ovarian cancer [2C73] [23]
Oxymorphone DM65AGJ Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Oxymorphone. Pain [MG30-MG3Z] [22]
Dezocine DMJDB0Y Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Dezocine. Pain [MG30-MG3Z] [22]
Nalbuphine DMOSQGU Moderate Additive cardiorespiratory depression effects by the combination of Propofol and Nalbuphine. Pain [MG30-MG3Z] [22]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Propofol and Buprenorphine. Pain [MG30-MG3Z] [22]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Propofol and Hydrocodone. Pain [MG30-MG3Z] [22]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Propofol and Triclabendazole. Parasitic worm infestation [1F90] [23]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Propofol and Pimavanserin. Parkinsonism [8A00] [23]
Abametapir DM2RX0I Moderate Decreased metabolism of Propofol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [40]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Propofol and Famotidine. Peptic ulcer [DA61] [25]
Macimorelin DMQYJIR Moderate Increased risk of prolong QT interval by the combination of Propofol and Macimorelin. Pituitary gland disorder [5A60-5A61] [23]
Lefamulin DME6G97 Moderate Increased risk of prolong QT interval by the combination of Propofol and Lefamulin. Pneumonia [CA40] [23]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Propofol and Ritodrine. Preterm labour/delivery [JB00] [28]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Propofol and Degarelix. Prostate cancer [2C82] [23]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Propofol and ABIRATERONE. Prostate cancer [2C82] [23]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Propofol and Enzalutamide. Prostate cancer [2C82] [23]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Propofol and Bicalutamide. Prostate cancer [2C82] [23]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Propofol and Levomepromazine. Psychotic disorder [6A20-6A25] [23]
Gatifloxacin DMSL679 Moderate Increased risk of prolong QT interval by the combination of Propofol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [23]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Propofol and Quetiapine. Schizophrenia [6A20] [23]
Mesoridazine DM2ZGAN Moderate Increased risk of prolong QT interval by the combination of Propofol and Mesoridazine. Schizophrenia [6A20] [23]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Propofol and Aripiprazole. Schizophrenia [6A20] [23]
Iloperidone DM6AUFY Moderate Increased risk of prolong QT interval by the combination of Propofol and Iloperidone. Schizophrenia [6A20] [23]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Propofol and Paliperidone. Schizophrenia [6A20] [23]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Propofol and Trifluoperazine. Schizophrenia [6A20] [23]
Amisulpride DMSJVAM Moderate Increased risk of prolong QT interval by the combination of Propofol and Amisulpride. Schizophrenia [6A20] [23]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Propofol and Asenapine. Schizophrenia [6A20] [23]
Pimozide DMW83TP Moderate Increased risk of prolong QT interval by the combination of Propofol and Pimozide. Schizophrenia [6A20] [23]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Propofol and Vardenafil. Sexual dysfunction [HA00-HA01] [23]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Propofol caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [29]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Propofol and LEE011. Solid tumour/cancer [2A00-2F9Z] [23]
Vandetanib DMRICNP Moderate Increased risk of prolong QT interval by the combination of Propofol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [23]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Propofol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [23]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Propofol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [23]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Propofol and Pitolisant. Somnolence [MG42] [23]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Propofol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [23]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Propofol and Lenvatinib. Thyroid cancer [2D10] [23]
Cabozantinib DMIYDT4 Moderate Increased risk of prolong QT interval by the combination of Propofol and Cabozantinib. Thyroid cancer [2D10] [23]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Propofol and Papaverine. Tonus and reflex abnormality [MB47] [41]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Propofol and Tacrolimus. Transplant rejection [NE84] [23]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Propofol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [35]
Procainamide DMNMXR8 Moderate Increased risk of prolong QT interval by the combination of Propofol and Procainamide. Ventricular tachyarrhythmia [BC71] [23]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Propofol and Propafenone. Ventricular tachyarrhythmia [BC71] [23]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Propofol and Flecainide. Ventricular tachyarrhythmia [BC71] [23]
⏷ Show the Full List of 157 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Egg phospholipids E00719 52922414 Surfactant; Dispersing agent; Emulsifying agent; Emulsion stabilizing agent; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Glyceryl monolinoleate E00639 Not Available Other agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Propofol 200mg/20ml injectable 200mg/20ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5464).
2 Propofol FDA Label
3 Propofol and sedation in patients with coronavirus disease. Am J Emerg Med. 2020 Jun 18;S0735-6757(20)30512-X.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
8 Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
9 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
10 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
11 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
12 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
13 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
16 Update of TTD: therapeutic target database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91.
17 Propofol suppresses proliferation, migration, invasion, and tumor growth of liver cancer cells via suppressing cancer susceptibility candidate 9/phosphatase and tensin homolog/AKT serine/threonine kinase/mechanistic target of rapamycin kinase axis. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211065972. doi: 10.1177/09603271211065972.
18 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
19 Evaluation of cytotoxicity of propofol and its related mechanism in glioblastoma cells and astrocytes. Environ Toxicol. 2017 Dec;32(12):2440-2454.
20 Sevoflurane but not propofol enhances ovarian cancer cell biology through regulating cellular metabolic and signaling mechanisms. Cell Biol Toxicol. 2023 Aug;39(4):1395-1411. doi: 10.1007/s10565-022-09766-6. Epub 2022 Oct 8.
21 Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols bioorg. Med Chem. 2009 Apr 15;17(8):3207-11.
22 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
23 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
24 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
25 Cerner Multum, Inc. "Australian Product Information.".
26 McClune S, McKay AC, Wright PM, et al "Synergistic interaction between midazolam and propofol." Br J Anaesth 69 (1992): 240-5. [PMID: 1389840]
27 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
28 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
29 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30 Canadian Pharmacists Association.
31 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
32 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
33 Cerner Multum, Inc. "Canadian Product Information.".
34 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
35 Scalese MJ, Herring HR, Rathburn RC, Skrepnek GH, Ripley TL "Propofol-associated QTc prolongation." Ther Adv Drug Saf 7 (2016): 68-78. [PMID: 27298717]
36 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
37 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
38 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
40 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
41 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]